How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine
The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not...
Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...
This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
Advanced Purchase Agreements for Covid-19 Vaccines: Do they ensure Global Public Good?
Advanced Purchase Agreements (APAs) were part of a strategy to provide upfront financing for Covid-19 vaccines and to accelerate their development and availability. Since...
Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
In October of 2020, 9 months into the pandemic, fearing conflicts over intellectual property (IP) related to medical measures to fight the pandemic, India...
How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the...
Patents usually confer 20-year exclusive rights on inventions. Data exclusivity laws confer, depending on the country, 5 to 10 years’ exclusive rights over safety...
WTO Covid-19 TRIPS Decision: Some observations
This morning, 17 June at 5 AM the 12th World Trade Organization (WTO) Ministerial Conference (MC12) approved a package of decisions and declarations. The...
The last mile: A few suggestions for the WHO Pandemic Agreement’s last two weeks...
This technical briefing note is also available as a PDF here.
On 16 April, the Bureau of the Intergovernmental Negotiating Body (INB) to draft and...
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...